Rossari Biotech Limited — PPTs, 20-10-2024: Investor Presentation

Rossari Biotech Limited reported steady performance in Q2 FY25, achieving record revenues (Rs. 498.4 crore), EBITDA (Rs. 65.9 crore), and PAT (Rs. 35.3 crore), reflecting a year-over-year growth. Key developments include the establishment of a new subsidiary in UAE, acquisition plans for Unistar Thai Co., and a strategic land purchase for expansion. The management emphasizes a focus on innovation and sustainability to enhance global presence and drive future growth.